The Redwood Study for Alpha-1 Antitrypsin Deficiency–Associated Liver Disease Is Enrolling!

About the Redwood Study
You could be the key for the future of liver affected Alphas. Currently there are no approved treatments available for Alpha-1 liver Disease. The Redwood Study is a Phase 3 clinical trial that aims to change this.
The investigational study drug, TAK-999 (fazirsiran), aims to reduce the production of the abnormal Z-AAT protein and its buildup in the liver. The reduction in levels of the protein may result in a decrease in liver scarring.
The investigational study drug being evaluated alongside the placebo, which appears similar to TAK-999 but contains no active medication, may help researchers understand whether TAK- 999 can reduce liver scarring caused by Alpha-1 Liver Disease.
Who can participate in the Redwood Study?
The Redwood Study (TAK-999-3001) has recently updated their eligibility criteria, and you may be eligible if you:
- Are 18 to 75 years of age.
- Have not smoked any substance (defined as not inhaling and exhaling the fumes of a substance) daily for the past 6 months
- Have a confirmed or suspected diagnosis of the PiZZ genotype for Alpha-1 Liver Disease or have a family member with a confirmed or suspected diagnosis
- Do not have hepatocellular carcinoma (HCC).
All study participants will receive the assigned study treatment, study-related medical exams, and study-related laboratory tests at no cost. Reimbursement for travel expenses may be available. Further details about study support can be discussed with the study team.
If you are interested, a participating research site can confirm a diagnosis of Alpha-1 Liver Disease and genotype, as well as other study criteria to determine your eligibility.
Every advancement starts with volunteers like you. The Redwood Study is continuing to enroll patients and needs your help . Complete the Redwood Study Pre-Screening and Inquiry Form below and an Alpha-1 Research Registry Coordinator will reach out to provide you with more information about the study. You can also contact us at 1-877-228-7321 ext. 252 / 245 or alpha1registry@alpha1.org.
By answering the following questions, you agree to have the information you provide retained by the Alpha-1 Foundation and be contacted by phone or email (as provided).